PMC:7283670 / 129114-130093 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T106","span":{"begin":7,"end":28},"obj":"Body_part"},{"id":"T107","span":{"begin":24,"end":28},"obj":"Body_part"},{"id":"T108","span":{"begin":30,"end":33},"obj":"Body_part"},{"id":"T109","span":{"begin":100,"end":103},"obj":"Body_part"},{"id":"T110","span":{"begin":180,"end":189},"obj":"Body_part"},{"id":"T111","span":{"begin":242,"end":245},"obj":"Body_part"},{"id":"T112","span":{"begin":332,"end":336},"obj":"Body_part"},{"id":"T113","span":{"begin":865,"end":868},"obj":"Body_part"}],"attributes":[{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A111","pred":"fma_id","subj":"T111","obj":"http://purl.org/sig/ont/fma/fma0326143"},{"id":"A112","pred":"fma_id","subj":"T112","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A113","pred":"fma_id","subj":"T113","obj":"http://purl.org/sig/ont/fma/fma0326143"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T243","span":{"begin":332,"end":336},"obj":"Body_part"}],"attributes":[{"id":"A243","pred":"uberon_id","subj":"T243","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T705","span":{"begin":193,"end":201},"obj":"Disease"},{"id":"T706","span":{"begin":326,"end":343},"obj":"Disease"},{"id":"T708","span":{"begin":337,"end":343},"obj":"Disease"},{"id":"T709","span":{"begin":660,"end":675},"obj":"Disease"},{"id":"T710","span":{"begin":666,"end":675},"obj":"Disease"},{"id":"T711","span":{"begin":753,"end":757},"obj":"Disease"},{"id":"T712","span":{"begin":774,"end":778},"obj":"Disease"},{"id":"T713","span":{"begin":835,"end":839},"obj":"Disease"},{"id":"T714","span":{"begin":844,"end":863},"obj":"Disease"},{"id":"T715","span":{"begin":924,"end":932},"obj":"Disease"},{"id":"T716","span":{"begin":944,"end":953},"obj":"Disease"}],"attributes":[{"id":"A705","pred":"mondo_id","subj":"T705","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A706","pred":"mondo_id","subj":"T706","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A707","pred":"mondo_id","subj":"T706","obj":"http://purl.obolibrary.org/obo/MONDO_0015796"},{"id":"A708","pred":"mondo_id","subj":"T708","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A709","pred":"mondo_id","subj":"T709","obj":"http://purl.obolibrary.org/obo/MONDO_0006012"},{"id":"A710","pred":"mondo_id","subj":"T710","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A711","pred":"mondo_id","subj":"T711","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A712","pred":"mondo_id","subj":"T712","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A713","pred":"mondo_id","subj":"T713","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A714","pred":"mondo_id","subj":"T714","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A715","pred":"mondo_id","subj":"T715","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A716","pred":"mondo_id","subj":"T716","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T204","span":{"begin":7,"end":28},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T205","span":{"begin":30,"end":33},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T206","span":{"begin":43,"end":44},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T207","span":{"begin":100,"end":103},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T208","span":{"begin":242,"end":245},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T209","span":{"begin":254,"end":257},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T210","span":{"begin":332,"end":336},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T211","span":{"begin":332,"end":336},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T212","span":{"begin":456,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T213","span":{"begin":456,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T214","span":{"begin":460,"end":464},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"},{"id":"T215","span":{"begin":489,"end":491},"obj":"http://purl.obolibrary.org/obo/CLO_0001022"},{"id":"T216","span":{"begin":489,"end":491},"obj":"http://purl.obolibrary.org/obo/CLO_0007314"},{"id":"T217","span":{"begin":535,"end":536},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T218","span":{"begin":627,"end":628},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T219","span":{"begin":865,"end":868},"obj":"http://purl.obolibrary.org/obo/CL_0000134"},{"id":"T220","span":{"begin":897,"end":898},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5650","span":{"begin":456,"end":458},"obj":"Chemical"},{"id":"T80314","span":{"begin":489,"end":491},"obj":"Chemical"}],"attributes":[{"id":"A46031","pred":"chebi_id","subj":"T5650","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"},{"id":"A43175","pred":"chebi_id","subj":"T80314","obj":"http://purl.obolibrary.org/obo/CHEBI_30145"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1063","span":{"begin":0,"end":42},"obj":"Sentence"},{"id":"T1064","span":{"begin":43,"end":202},"obj":"Sentence"},{"id":"T1065","span":{"begin":203,"end":344},"obj":"Sentence"},{"id":"T1066","span":{"begin":345,"end":519},"obj":"Sentence"},{"id":"T1067","span":{"begin":520,"end":758},"obj":"Sentence"},{"id":"T1068","span":{"begin":759,"end":979},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T329","span":{"begin":326,"end":343},"obj":"Phenotype"},{"id":"T330","span":{"begin":666,"end":675},"obj":"Phenotype"},{"id":"T331","span":{"begin":844,"end":863},"obj":"Phenotype"},{"id":"T332","span":{"begin":944,"end":953},"obj":"Phenotype"}],"attributes":[{"id":"A329","pred":"hp_id","subj":"T329","obj":"http://www.orpha.net/ORDO/Orphanet_178320"},{"id":"A330","pred":"hp_id","subj":"T330","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A331","pred":"hp_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A332","pred":"hp_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2679","span":{"begin":307,"end":313},"obj":"Species"},{"id":"2680","span":{"begin":481,"end":485},"obj":"Species"},{"id":"2681","span":{"begin":774,"end":784},"obj":"Species"},{"id":"2682","span":{"begin":193,"end":201},"obj":"Disease"},{"id":"2683","span":{"begin":326,"end":343},"obj":"Disease"},{"id":"2684","span":{"begin":660,"end":675},"obj":"Disease"},{"id":"2685","span":{"begin":753,"end":757},"obj":"Disease"},{"id":"2686","span":{"begin":835,"end":839},"obj":"Disease"},{"id":"2687","span":{"begin":844,"end":863},"obj":"Disease"},{"id":"2688","span":{"begin":924,"end":932},"obj":"Disease"},{"id":"2689","span":{"begin":944,"end":953},"obj":"Disease"}],"attributes":[{"id":"A2679","pred":"tao:has_database_id","subj":"2679","obj":"Tax:10090"},{"id":"A2680","pred":"tao:has_database_id","subj":"2680","obj":"Tax:163112"},{"id":"A2681","pred":"tao:has_database_id","subj":"2681","obj":"Tax:2697049"},{"id":"A2682","pred":"tao:has_database_id","subj":"2682","obj":"MESH:C000657245"},{"id":"A2683","pred":"tao:has_database_id","subj":"2683","obj":"MESH:D055371"},{"id":"A2685","pred":"tao:has_database_id","subj":"2685","obj":"MESH:D012128"},{"id":"A2686","pred":"tao:has_database_id","subj":"2686","obj":"MESH:D012128"},{"id":"A2687","pred":"tao:has_database_id","subj":"2687","obj":"MESH:D012131"},{"id":"A2688","pred":"tao:has_database_id","subj":"2688","obj":"MESH:C000657245"},{"id":"A2689","pred":"tao:has_database_id","subj":"2689","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"7.5.2 Mesenchymal stem cell (MSC) therapy\nA new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu \u0026 Li, 2018; Wang, Yao, Lv, Ling, \u0026 Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020)."}